About
Dr Thomas Hwang is Director of the Cancer Innovation and Regulation Initiative and Assistant Professor at Harvard Medical School.
Dr Hwang is an expert in pharmaceutical and device regulation and reimbursement. A physician and health policy researcher, his work focuses on new medicines, medical devices, and digital health interventions in cancer care.
Dr Hwang has published over 100 peer-reviewed papers, including in the New England Journal of Medicine, JAMA, Lancet, and Lancet Oncology. He serves on the European Society for Medical Oncology’s Working Group on the Magnitude of Clinical Benefit Scale, and in 2023 he was named one of STAT’s “Wunderkinds” as one of the nation’s leading experts on pharmaceutical regulation.
Previously, Dr Hwang was a Visiting Expert at the European Medicines Agency and has work experience in venture capital, the World Health Organization, and the White House. He received his undergraduate and medical degrees from Harvard, where he was the 21st recipient of summa cum laude in Harvard Medical School’s history.